TrialSite has learned of material information regarding mRNA vaccine safety that was revealed by a freedom of information act request (FOIA). The FOIA documents reveal animal study results demonstrating that the Pfizer mRNA-based vaccine does not remain at the injection site, but rather appears to spread widely after injection.
In addition, a paper published in the journal Clinical Infectious Diseases on May 20th, 2021 (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075), also found that the spike protein was present in the plasma of those who received the vaccine. These were Harvard scientists who demonstrated that the spike protein travels throughout the body and doesn't stay in the area of original injection.
Again, this is important when we understand that the spike protein itself causes damage to organs in the body. According to the documents, pre-clinical studies show that the active part of the vaccine (mRNA-lipid nanoparticles), which produce the spike protein, spreads throughout the body and is then concentrated in various organs, including the ovaries and spleen.
TrialSite also learned, via regulatory documents, that Pfizer did not follow industry-standard quality management practices during preclinical toxicology studies during vaccine production, as key studies did not meet good laboratory practice (GLP). Regulatory documents also show Pfizer did not follow industry-standard quality management practices during preclinical toxicology studies of its vaccine, as key studies did not meet good laboratory practice (GLP).
Good laboratory practice or GLP is a set of principles intended to assure the quality and integrity of non-clinical laboratory studies used as the basis for research or marketing permits for products regulated by government agencies. Once again, as time goes on, we will certainly learn more and my goal here is to simply share the information that is out there, so you can be informed, empowered and make better decisions.
0 Comments